
AGMB Stock Forecast & Price Target
AGMB Analyst Ratings
Bulls say
AgomAb Therapeutics is paving the way for novel disease-modifying therapies for chronic fibrotic indications with high unmet medical need, making it an attractive investment for those seeking to capitalize on the rising demand for effective treatments in this space. While there are challenges within the development of antifibrotic treatments, the company's pipeline, particularly Ontunisertib, has shown promising results and is backed by strong financials. With the company's focus on addressing limitations associated with prior treatment approaches and expanding into other indications like Crohn's disease and liver disease, the future looks bright for AgomAb Therapeutics and its potential impact on improving patient outcomes.
Bears say
AgomAb Therapeutics is a promising clinical-stage company targeting fibrotic diseases with a well-validated anti-fibrotic target and innovative pharmacokinetic strategy to avoid side effects. With a first-mover advantage in the market and multiple drugs in development—including Ontunisertib and AGMB-447—the company has potential for high sales and is forecasting high revenue. Further progress and potential partnerships in 2026 are expected to drive growth and reinforce its position in this growing market.
This aggregate rating is based on analysts' research of AgomAb Therapeutics SA and is not a guaranteed prediction by Public.com or investment advice.
AGMB Analyst Forecast & Price Prediction
Start investing in AGMB
Order type
Buy in
Order amount
Est. shares
0 shares